CC BY-NC-ND 4.0 · Journal of Cardiac Critical Care TSS 2022; 06(03): 206-209
DOI: 10.1055/s-0042-1759804
Review Article

Beta-Adrenergic Blockade: Is It the Prudent Choice against Sympathetic Overdrive in Patients with Hypertension or Heart Failure?

H.K Chopra
1   Department of Cardiology, Medanta Moolchand Heart Institute - Moolchand Medcity, New Delhi, India
,
A.K Pancholia
2   Department of Medicine and Preventive Cardiology, Arihant Hospital and Research Center, Indore, Madhya Pradesh, India
,
Bhupen N. Desai
3   Department of Cardiology, Desai Heart Care Clinic, Mumbai, Maharashtra, India
,
Ajay K. Sinha
4   Department of Clinical Cardiology and Research, Jaiprabha Medanta Super Speciality Hospital, Patna, Bihar, India
,
Dhammdeep Dabhade
5   Department of Medical Services, Emcure Pharmaceuticals Ltd., Pune, Maharashtra, India
,
Sanket Newale
5   Department of Medical Services, Emcure Pharmaceuticals Ltd., Pune, Maharashtra, India
› Author Affiliations

Abstract

The development of hypertension and heart failure is correlated with the hyperactivation of the sympathetic nervous system. Beta-blockers are often considered a good therapeutic option in such clinical scenarios. However, the choice of β-blocker is a concern because of certain aspects like associated metabolic disturbances with their usage. Metoprolol has been reported to have the potential to alleviate sympathetic overdrive in patients with hypertension and heart failure. S-Metoprolol is the chirally pure β-blocker with favorable pharmacological features, improved safety profile, and allied clinical advantages versus racemic metoprolol; given this, can it be an effective therapeutic option against sympathetic overdrive in patients with hypertension and/or heart failure is not fully recognized yet. In this review, we attempted to discuss the current facts around sympathetic overdrive linked with hypertension as well as heart failure and pertaining pharmacological intervention with a focus on β-blockers in these clinical situations with an emphasis on the likely beneficial role of S-metoprolol.

Disclosure

The views expressed in this publication represent those of the author(s).




Publication History

Article published online:
03 December 2022

© 2022. Official Publication of The Simulation Society (TSS), accredited by International Society of Cardiovascular Ultrasound (ISCU). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Gordan R, Gwathmey JK, Xie LH. Autonomic and endocrine control of cardiovascular function. World J Cardiol 2015; 7 (04) 204-214
  • 2 Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 2007; 17 (06) 473-481
  • 3 Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 2006; 29 (11) 839-847
  • 4 Grassi G, Seravalle G, Quarti-Trevano F. The ‘neuroadrenergic hypothesis’ in hypertension: current evidence. Exp Physiol 2010; 95 (05) 581-586
  • 5 Morris J, Dunham A. Metoprolol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. 2021 Jul 13
  • 6 Moreira MC, Pinto IS, Mourão AA. et al. Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome?. Front Physiol 2015; 6: 234
  • 7 Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015; 116 (06) 976-990
  • 8 Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18 (02) 73-78
  • 9 Anchala R, Kannuri NK, Pant H. et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens 2014; 32 (06) 1170-1177
  • 10 Padmanabhan TN, Dani S, Chopra VK, Guha S, Vasnawala H, Ammar R. Prevalence of sympathetic overactivity in hypertensive patients - a pan India, non-interventional, cross sectional study. Indian Heart J 2014; 66 (06) 686-690
  • 11 Rao D, Balagopalan JP, Sharma A, Chauhan VC, Jhala D. BEAT Survey: A cross-sectional study of resting heart rate in young (18-55 year) hypertensive patients. J Assoc Physicians India 2015; 63 (05) 14-17
  • 12 Kaul U, Wander GS, Sinha N. et al. Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study. J Hypertens 2020; 38 (07) 1262-1270
  • 13 Grassi G, D'Arrigo G, Pisano A. et al. Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis. J Hypertens 2019; 37 (09) 1746-1756
  • 14 Grassi G. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. J Cardiol Pract 2015; 13: 24
  • 15 Cruickshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol 2017; 956: 149-166
  • 16 Mohsen Ibrahim. The Egyptian Hypertension Society Egyptian hypertension guidelines. Egypt Heart J 2014; 66: 79-132
  • 17 Olawi N, Krüger M, Grimm D, Infanger M, Wehland M. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol 2019; 125 (03) 189-201
  • 18 National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. London: Royal College of Physicians (UK); 2011 Aug
  • 19 Frishman WH. A historical perspective on the development of β-adrenergic blockers. J Clin Hypertens 2007; 9: 19-27
  • 20 Nadkar MY, Tiwaskar M, Kalra S. et al. Association of Physicians of India: position statement on role of chirally pure molecules in clinical practice. J Assoc Physicians India 2017; 65 (12) 49-60
  • 21 Mandora VP. Safety and efficacy of S-metoprolol succinate extended-release tablet in the treatment of hypertension coexisting with COPD. Ind Med Gaz 2006; x: 28-32
  • 22 Jayaram S, Kaul U, Pai V, Pandit A, Pathak L, Shinde S. The SMART trial: S-metoprolol assessment in hypertension trial. Cardiology Today. 2005; 9: 222-229
  • 23 SMART-II Study Group. Results of SMART-II study on efficacy and safety of S-Metoprolol extended-release tablet. Ind Med Gaz 2006; CXL(2) 72-75
  • 24 Aneja P, Srinivas A, Biswas AD. Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. Int J Clin Pharmacol Ther 2007; 45 (05) 253-258
  • 25 Talwalkar P. G.- Safety and Efficacy of S-Metoprolol in the Treatment of Patients with Diabetes Mellitus and Hypertension (SMART-DIMENSION Study). Ind Med Gaz 2007; CXLI (04) 139-144
  • 26 Ramesh D, Kumar PS, Palimkar P, Dhoot K, Dabhade DC, Newale S. Nationwide surveillance for S-Metoprolol treatment effect on blood pressure control against sympathetic overdrive in Indian patients with hypertension (PROTECT). Int J Adv Med 2022; 9 (03) 249-252 cited 2022 Oct 6
  • 27 Mohan JC, Shah SN, Chinchansurkar S, Dey A, Jain R. Rediscovering Chirality - Role of S-metoprolol in cardiovascular disease management. J Assoc Physicians India 2017; 65 (06) 74-79